株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

非アルコール性脂肪性肝炎 (NASH) 治療薬の世界市場:考察、動向、予測

Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Insights, Trends and Forecast (2019-2028)

発行 Koncept Analytics 商品コード 908791
出版日 ページ情報 英文 96 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
非アルコール性脂肪性肝炎 (NASH) 治療薬の世界市場:考察、動向、予測 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Insights, Trends and Forecast (2019-2028)
出版日: 2019年08月26日 ページ情報: 英文 96 Pages
概要

当レポートでは、世界の非アルコール性脂肪性肝炎 (NASH) 市場について調査分析し、市場概要、市場分析、地域別市場分析、市場力学、競合情勢、主要企業などについて、体系的な情報を提供しています。

第1章 市場概要

  • イントロダクション
  • 病因 & 症状
  • 診断
  • 治療
  • オフラベル医薬品
  • 治療処置

第2章 世界のNASH市場

  • 世界のNASH治療薬市場予測 (金額ベース)
  • 世界のNASH治療薬市場規模予測 (金額ベース) :薬剤クラス別
  • 世界のNASHオフラベル治療薬市場の予測 (金額ベース)

第3章 世界のNASH治療薬市場

  • 世界のNASH治療薬市場 (金額ベース)
  • 世界のNASH治療薬市場予測 (金額ベース) :薬剤クラス別
  • 世界のNASH治療薬市場予測 (金額ベース) :地域別

第4章 地域のNASH治療薬

  • 米国
  • 欧州
  • その他 (ROW)

第5章 市場力学

  • 成長促進要因
  • 主要動向・発展
  • 課題

第6章 競合情勢

  • 世界市場

第7章 企業プロファイル

  • Bristol Myers Squibb
  • Gilead Sciences, Inc.
  • Allergan Plc (Tobira)
  • Intercept Pharmaceuticals, Inc.
  • Galmed Pharmaceuticals
  • Genfit SA
目次

The global Non-Alcoholic Steatohepatitis (NASH) drugs market is expected to reach US$61.60 billion in 2028, growing at a CAGR of 39.36%, for the duration spanning 2018-2028. The factors such as rising prevalence of NASH, increasing diabetic population, rising obesity, unmet medical needs and sedentary lifestyle are expected to drive the growth of the market. However, the market growth would be challenged by lethargic drug approval process, high treatment cost and less definitive diagnostic methods for NASH/NAFLD. A few notable trends include escalating market penetration for NASH major drugs, progressing NASH diagnosis methods and biomarkers, NASH pipeline drugs under development and growth in E-Commerce pharmaceutical products sales.

The global Non-Alcoholic Steatohepatitis (NASH) drugs market has two major segments, based on drug classes - Off-Label drugs and Therapeutic Drugs. The current NASH drugs market is wholly occupied by off-label drugs as there are no clinically approved medicines for the treatment of NASH. However, certain therapeutic drugs, from large pharmaceutical drugs, are expected to enter the market in coming years, with considerable market share. The need for definitive NASH treatment would lead to strong market penetration of the therapeutic drugs during the forecasted period.

The fastest growing regional market would be the U.S., due to the increasing prevalence of NASH, along with forthcoming launches of various NASH therapeutic drugs. Moreover, Europe is also expected to hold a significant share in the global NASH therapeutics market, owing to the growing awareness amongst the inhabitants, regarding NASH diagnosis and treatment methods.

Scope of the report:

The report provides a comprehensive analysis of the global Non-Alcoholic Steatohepatitis (NASH) Drugs market, segmented into Off Label Drugs and Therapeutic Drugs sub markets.

The major regional markets (the U.S. and Europe) have been analyzed.

The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.

The competitive landscape of the market, along with the company profiles of leading players (Bristol Myers Squibb, Gilead Sciences, Allergan Plc. (Tobira), Intercept Pharmaceuticals, Galmed Pharmaceuticals and Genfit SA) are also presented in detail.

Key Target Audience:

  • NAFLD/NASH Drugs Manufacturers
  • Chemical Suppliers
  • End Users (Hospital, Medical centers, Clinical Institutes)
  • Healthcare Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities

Table of Contents

1. Market Overview

  • 1.1 Introduction
  • 1.2 Causes & Symptoms
  • 1.3 Diagnosis
  • 1.4 Treatment
  • 1.5 Off-Label Treatment
  • 1.6 Therapeutic Treatment

2. Global NASH Market

  • 2.1 Global NASH Drugs Market Forecast by Value
  • 2.2 Global NASH Drugs Market Value Forecast by Drug Class
  • 2.3 Global NASH Off-Label Drugs Market Forecast by Value

3. Global NASH Therapeutics Market

  • 3.1 Global NASH Therapeutics Market Forecast by Value
  • 3.2 Global NASH Therapeutics Market Value Forecast by Drug Type
    • 3.2.1 Global NASH Therapeutics Market Value Forecast by Drug Type (2023)
    • 3.2.2 Global NASH Therapeutics Market Value Forecast by Drug Type (2028)
    • 3.2.3 Global Obeticholic Acid (OCA) Drug Market Forecast by Value
    • 3.2.4 Global Obeticholic Acid (OCA) Drug Market Value Forecast by Region
    • 3.2.5 Global Cenicriviroc (CVC) Drug Market Forecast by Value
    • 3.2.6 Global Cenicriviroc (CVC) Drug Market Value Forecast by Region
    • 3.2.7 Global Elafibranor Drug Market Forecast by Value
    • 3.2.8 Global Aramchol Drug Market Forecast by Value
    • 3.2.9 Global MGL-3196 Drug Market Forecast by Value
    • 3.2.10 Global INN-217 Drug Market Forecast by Value
    • 3.2.11 Global VK2809 Drug Market Forecast by Value
  • 3.3 Global NASH Therapeutics Market Value Forecast by Region
    • 3.3.1 Global NASH Therapeutics Market Value Forecast by Region (2023)
    • 3.3.2 Global NASH Therapeutics Market Value Forecast by Region (2028)

4. Regional NASH Market

  • 4.1 The U.S. NASH Therapeutics Market Forecast by Value
  • 4.2 Europe NASH Therapeutics Market Forecast by Value
  • 4.3 ROW NASH Therapeutics Market Forecast by Value

5. Market Dynamics

  • 5.1 Growth Drivers
    • 5.1.1 Rising Prevalence of NASH
    • 5.1.2 Rising HealthCare Expenditure
    • 5.1.3 Increasing Diabetic Population
    • 5.1.4 Rising Obesity
    • 5.1.5 Unmet Medical Needs
    • 5.1.6 Sedentary Lifestyle
  • 5.2 Key Trends & Development
    • 5.2.1 Escalating Market Penetration for NASH Major Drugs
    • 5.2.2 Increase in Pharmaceutical R&D Expenditures
    • 5.2.3 Progressing NASH Diagnosis Methods and Biomarkers
    • 5.2.4 NASH Pipeline Drugs under Development
    • 5.2.5 Growth in E-Commerce Pharmaceutical Products Sales
  • 5.3 Challenges
    • 5.3.1 Lethargic Drug Approval Process
    • 5.3.2 High Treatment Cost
    • 5.3.3 Associated Business Risk
    • 5.3.4 Less Definitive Diagnostic Methods for NASH/NAFLD

6. Competitive Landscape

  • 6.1 Global NASH Drugs Market
    • 6.1.1 Key Players - Product Portfolio Comparison
    • 6.1.2 Key Players - Phase II clinical trials in NASH with histological endpoints Comparison
    • 6.1.3 Key Players - R&D Comparison
    • 6.1.4 Key Players - Revenue Comparison
    • 6.1.5 Key Players - Market Cap Comparison

7. Company Profiles

  • 7.1 Bristol Myers Squibb
    • 7.1.1 Business Overview
    • 7.1.2 Financial Overview
    • 7.1.3 Business Strategies
  • 7.2 Gilead Sciences, Inc.
    • 7.2.1 Business Overview
    • 7.2.2 Financial Overview
    • 7.2.3 Business Strategies
  • 7.3 Allergan Plc (Tobira)
    • 7.3.1 Business Overview
    • 7.3.2 Financial Overview
    • 7.3.3 Business Strategies
  • 7.4 Intercept Pharmaceuticals, Inc.
    • 7.4.1 Business Overview
    • 7.4.2 Financial Overview
    • 7.4.3 Business Strategies
  • 7.5 Galmed Pharmaceuticals
    • 7.5.1 Business Overview
    • 7.5.2 Financial Overview
    • 7.5.3 Business Strategies
  • 7.6 Genfit SA
    • 7.6.1 Business Overview
    • 7.6.2 Financial Overview
    • 7.6.3 Business Strategies

List of Figures

  • NAFLD Spectrum and Estimated Advancement Risk
  • Treatment of NASH
  • Potential Phase III NASH Drugs
  • Global NASH Drugs Market Forecast by Value (2018-2028)
  • Global NASH Drugs Market Value Forecast by Drug Class (2018/2023/2028)
  • Global NASH Off-Label Drugs Market Forecast by Value (2018-2028)
  • Global NASH Therapeutics Market Forecast by Value (2020-2028)
  • Global NASH Therapeutics Market Value Forecast by Drug Type (2023)
  • Global NASH Therapeutics Market Value Forecast by Drug Type (2028)
  • Global Obeticholic Acid (OCA) Drug Market Forecast by Value (2020-2028)
  • Global Obeticholic Acid (OCA) Drug Market Value Forecast by Region (2028)
  • Global Cenicriviroc (CVC) Drug Market Forecast by Value (2020-2028)
  • Global Cenicriviroc (CVC) Drug Market Value Forecast by Region (2028)
  • Global Elafibranor Drug Market Forecast by Value (2020-2028)
  • Global Aramchol Drug Market Forecast by Value (2022-2028)
  • Global MGL-3196 Drug Market Forecast by Value (2023-2028)
  • Global INN-217 Drug Market Forecast by Value (2023-2028)
  • Global VK2809 Drug Market Forecast by Value (2023-2028)
  • Global NASH Therapeutics Market Value Forecast by Region (2023)
  • Global NASH Therapeutics Market Value Forecast by Region (2028)
  • The U.S. NASH Therapeutics Market Forecast by Value (2022-2028)
  • Europe NASH Therapeutics Market Forecast by Value (2022-2028)
  • ROW NASH Therapeutics Market Forecast by Value (2022-2028)
  • The U.S. NASH Patient Population (2018-2028)
  • Global HealthCare Expenditure Per Capita (2014-2018)
  • Global Diabetic Population (2014-2018)
  • Global Obese Patient Population (2014-2018)
  • Number of NASH Patients treated with Ocaliva and Selonsertib Forecast (2020-2025)
  • Global Pharmaceutical R&D Expenditures (2014-2018)
  • Global E-Commerce Pharmaceutical Products Sales (2018-2023)
  • Drugs Approval Process
  • Key Players - R&D Comparison (2017-2018)
  • Bristol Myers Squibb Total Revenue and Net Earnings (2014-2018)
  • Bristol Myers Squibb Total Revenue by Segments (2018)
  • Bristol Myers Squibb Total Revenue by Regions (2018)
  • Gilead Sciences Total Revenues and Net Income (2014-2018)
  • Gilead Sciences Total Revenues by Business Segments (2018)
  • Gilead Sciences Total Revenues by Regions (2018)
  • Allergan Plc. (Tobira) Net Revenues and Net Loss (2014-2018)
  • Allergan Plc. (Tobira) Net Revenues by Segments (2018)
  • Allergan Plc. (Tobira) Net Revenues by Regions (2018)
  • Intercept Pharmaceuticals Revenue and Net Loss (2014-2018)
  • Intercept Pharmaceuticals Revenue by Segments (2018)
  • Galmed Pharmaceuticals Revenue and Net Loss (2014-2018)
  • Genfit SA Revenue and Net Loss (2014-2018)

List of Tables

  • NASH Off-Label Therapies
  • Selected NASH Diagnosis Methods and Biomarkers under Development (2018)
  • Drugs under Development for NASH (2018)
  • Key Players - Product Portfolio Comparison (2018)
  • Key Players - Phase II clinical trials in NASH with histological endpoints Comparison
  • Key Players - Revenue Comparison (2018)
  • Key Players - Market Cap Comparison (2019)
  • Intercept Pharmaceuticals Product Pipeline (2018)
  • Genfit SA Product Pipeline (2018)
Back to Top